We fully understand that building productive relationships with business, technology, development, and supplier partners is essential to fulfilling our short- and long-term goals for our company – and for the future of healthcare. Every collaborative effort takes us one step closer to making new discoveries, advancing and expanding our pipeline, achieving commercial success and ultimately, establishing a higher bar in radiation oncology.
We aim to benefit from each other’s value and expertise across a variety of capabilities.
We are developing multiple drug candidates in the radiotherapy space – a market experiencing significant deal activity and R&D investment, and that is projected to grow significantly over the next 5 years.
A patented, targeted radiotherapeutic for brain and CNS cancers
Comprised of a BMEDA-chelated Rhenium-186 radiation particle (beta/gamma emitter), encapsulated within a 100-nanometer nanoliposome
Currently being evaluated in U.S. Phase 1 clinical trials: ReSPECT-GBM (supported by NIH/NCI) for recurrent glioblastoma and ReSPECT-LM for leptomeningeal metastases
A next-generation radioembolization therapy for the treatment of primary and secondary liver cancers
Comprised of a BMEDA-chelated Rhenium-188 radiation particle (beta/gamma emitter), encapsulated within a 100-nanometer nanoliposome and loaded into a biodegradable alginate 50-micrometer microsphere
A patented, targeted radiotherapeutic for brain and CNS cancers
Comprised of a BMEDA-chelated Rhenium-186 radiation particle (beta/gamma emitter), encapsulated within a 100-nanometer nanoliposome
Currently being evaluated in U.S. Phase 1 clinical trials: ReSPECT-GBM (supported by NIH/NCI) for recurrent glioblastoma and ReSPECT-LM for leptomeningeal metastases
A next-generation radioembolization therapy for the treatment of primary and secondary liver cancers
Comprised of a BMEDA-chelated Rhenium-188 radiation particle (beta/gamma emitter), encapsulated within a 100-nanometer nanoliposome and loaded into a biodegradable alginate 50-micrometer microsphere
A patented, targeted radiotherapeutic for brain and CNS cancers
Comprised of a BMEDA-chelated Rhenium-186 radiation particle (beta/gamma emitter), encapsulated within a 100-nanometer nanoliposome
Currently being evaluated in U.S. Phase 1 clinical trials: ReSPECT-GBM (supported by NIH/NCI) for recurrent glioblastoma and ReSPECT-LM for leptomeningeal metastases
A next-generation radioembolization therapy for the treatment of primary and secondary liver cancers
Comprised of a BMEDA-chelated Rhenium-188 radiation particle (beta/gamma emitter), encapsulated within a 100-nanometer nanoliposome and loaded into a biodegradable alginate 50-micrometer microsphere
We are always looking for new suppliers and vendors to help us in the areas of raw materials, product and clinical development, analytical chemistry, manufacturing, quality, regulatory affairs, and industry partnerships.
Current Partners
